Sangamo BioSciences And City of Hope Granted Strategic Partnership Award From California Institute for Regenerative Medicine To Support Clinical Trial Of Stem-Cell Based ZFP Therapeutic For HIV/AIDS
"Sangamo's powerful and precise ZFN-mediated genome editing technology allows us to modify a patient's own stem cells and perform 'autologous' transplants, with the potential to replicate the functional cure obtained for the 'Berlin Patient' in any HIV-infected individual," said
The four-year grant provides matching funds to support evaluation of Sangamo's stem cell-based ZFP Therapeutic in HIV-infected individuals in a clinical trial conducted at
CCR5 encodes a critical co-receptor for HIV infection of immune cells. A naturally occurring mutation of the CCR5 gene, CCR5 delta-32, results in the loss of expression of the CCR5 protein on the surface of immune cells. Individuals who carry the CCR5 delta-32 mutation on both copies of their CCR5 gene (CCR5 delta-32 homozygotes) are not susceptible to the most common strain of HIV. One HIV-infected individual, known as the 'Berlin Patient,' underwent stem cell transplantation with HSPCs from a CCR5 delta-32 homozygote achieving what is considered to be a "functional cure" of his HIV and enabling him to remain off antiretroviral medication for more than six years. As stem cell transplantation is limited by the availability of HLA-matched, homozygous CCR5 delta-32 donors, Sangamo's approach is designed to make HIV-infected individuals their own donor using ZFN technology to disrupt the CCR5 gene in their HSPCs.
Sangamo's ZFN-mediated genome-editing technology has already been successfully applied to the generation of CCR5-modified autologous CD4 T-cells (SB-728-T), a program which is currently in a Phase 2 clinical trial in HIV-1 infected subjects. A number of clinical studies, in more than 70 subjects, have demonstrated that SB-728-T treatment is generally safe and well-tolerated. Of importance to the HSPC approach, the ZFN-modified CCR5-edited T-cells engraft, persist over time, and traffic throughout the body, including sites such as the gut-associated lymphoid tissue, that house the viral reservoir. The reservoir is a "store" of the virus that cannot be diminished by treatment with antiretroviral medications. In contrast, clinical data support the erosion of this reservoir in SB-728-T-treated subjects over time. Immunologic analyses have also provided insight into baseline immunologic parameters that are required for the successful engraftment of SB-728-T, and include the inflammatory status of the HIV-infected individual.
Treatment for HIV-1 infection with ART results in diminished HIV-1 replication and increased CD4 cell counts. However, CD4 cell counts fail to recover in approximately 20% HIV-1 infected patients, despite optimal treatment and completely suppressed viral replication and these individuals, known as immunologic non-responders (INR), are at significant risk from progressive AIDS-related syndromes. The suboptimal immune reconstitution in INR patients is thought to be influenced by several factors, including previous therapeutic failure, duration of anti-retroviral therapy, low CD4 counts at the initiation of ART, and persistent chronic immune activation, or inflammation, which makes them poor candidates for good SB-728-T engraftment. SB-728mR-HSPC is being developed as a new therapeutic strategy for this INR population.
The primary objective of the Phase 1, open-label study is to evaluate the safety and tolerability of the infusion of autologous ZFN-genome-edited, CCR5-disrupted HSPCs (SB-728mR-HSPC) in HIV-1 infected subjects who are on ART, have no detectable virus in the circulation, but have sub-optimal CD4 T-cell levels. Secondary objectives of the trial are to assess the engraftment and biologic activity of the infused CCR5 modified HSPCs cells that may help to define primary efficacy endpoints for future studies. These secondary objectives include engraftment, persistence and trafficking of the CCR5-disrupted HSPCs, effect of these cells on plasma viral loads during treatment interruption from ART and longitudinal changes in the viral reservoir.
"This is the first of several clinical applications of ZFN-based technology in stem cells," said
"CIRM continues to provide valuable support for innovative stem cell-based therapeutics," continued
"These programs help bring together the most rigorous scientific research with companies that know how to do clinical trials and move therapies through the regulatory process," said
Most Popular Stories
- GE Healthcare Bringing Jobs to Massachusetts
- Faith Groups Divest From Fossil Fuels
- Hispanic NASCAR Driver Ready to Make History
- James Foley Killer Could Be ID'd Via Social Media, Voice Recognition
- James Foley Beheading Video Is Real Thing: White House
- Apple Stock Bounces Back Big Time
- Bank of America Agrees to Pay Record $16.65 Billion
- U.S. Existing Home Sales Rise 4th Month Straight
- Entrepreneur Contest Announced in Idaho
- Family Dollar Will Stick With Dollar Tree